Cubist Systematic Strategies LLC Buys 6,121 Shares of Indivior PLC (NASDAQ:INDV)

Cubist Systematic Strategies LLC boosted its stake in Indivior PLC (NASDAQ:INDV) by 32.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,236 shares of the company’s stock after acquiring an additional 6,121 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Indivior were worth $407,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp acquired a new stake in Indivior in the 2nd quarter valued at approximately $188,000. VELA Investment Management LLC bought a new position in shares of Indivior during the 2nd quarter worth approximately $235,000. XTX Topco Ltd acquired a new stake in shares of Indivior in the second quarter valued at approximately $249,000. Cannon Global Investment Management LLC bought a new stake in shares of Indivior in the first quarter worth $563,000. Finally, Forsta AP Fonden acquired a new position in Indivior during the first quarter worth $641,000. 60.33% of the stock is owned by institutional investors and hedge funds.

Indivior Price Performance

Indivior stock opened at $7.46 on Monday. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of 746.00 and a beta of 0.68. The stock’s 50 day moving average is $10.99 and its 200-day moving average is $14.66. The company has a current ratio of 0.85, a quick ratio of 0.68 and a debt-to-equity ratio of 23.50. Indivior PLC has a 12 month low of $7.39 and a 12 month high of $23.22.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.40 by $0.04. Indivior had a negative net margin of 12.29% and a negative return on equity of 654.82%. The firm had revenue of $299.00 million during the quarter, compared to the consensus estimate of $285.90 million. Equities research analysts expect that Indivior PLC will post 1.7 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Craig Hallum decreased their price objective on Indivior from $20.00 to $16.00 and set a “buy” rating for the company in a report on Friday. Piper Sandler reaffirmed an “overweight” rating and set a $15.00 price target (down previously from $22.00) on shares of Indivior in a research report on Friday.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.